Advertisement

Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 2

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

Published on: 
, , ,

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Advertisement
Advertisement